scispace - formally typeset
N

Nora D. Volkow

Researcher at National Institute on Drug Abuse

Publications -  1038
Citations -  121498

Nora D. Volkow is an academic researcher from National Institute on Drug Abuse. The author has contributed to research in topics: Dopamine & Addiction. The author has an hindex of 165, co-authored 958 publications receiving 107463 citations. Previous affiliations of Nora D. Volkow include National Institutes of Health & North Shore University Hospital.

Papers
More filters
Journal ArticleDOI

Gene x disease interaction on orbitofrontal gray matter in cocaine addiction.

TL;DR: Long-term cocaine users with the low-repeat MAOA allele have enhanced sensitivity to gray matter loss, specifically in the orbitofrontal cortex, indicating that this genotype may exacerbate the deleterious effects of cocaine in the brain.
Journal ArticleDOI

Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain.

TL;DR: The findings indicate that in the human brain, caffeine, at doses typically consumed, increases the availability of DA D2/D3 receptors, which indicates that caffeine does not increase DA in the striatum for this would have decreased D2-D3 receptor availability.
Journal ArticleDOI

Effects of endogenous dopamine on measures of [18F]N-methylspiroperidol binding in the basal ganglia: comparison of simulations and experimental results from PET studies in baboons.

TL;DR: The effect of dopamine on specific binding was found to be greater in vivo than in vitro because the in vitro equilibrium experiment is controlled only by the relative Kd's of tracer and dopamine while the in vivo experiment also depends upon the halftime oftracer in tissue which is controlled by the tissue‐to‐plasma transport constant.
Journal ArticleDOI

Methylphenidate Decreased the Amount of Glucose Needed by the Brain to Perform a Cognitive Task

TL;DR: Findings corroborate prior findings that stimulant medications reduced the magnitude of regional activation to a task and in addition document a “focusing” of the activation and explain why methylphenidate has beneficial effects in some individuals and contexts and detrimental effects in others.